P53+/- hemizygous knockout mouse: overview of available data.
about
Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological StudiesSkp2B attenuates p53 function by inhibiting prohibitinMutagenicity of the peroxisome proliferators clofibrate, Wyeth 14,643 and di-2-ethylhexyl phthalate in the lacZ plasmid-based transgenic mouse mutation assayThe role of transgenic mouse models in carcinogen identificationTransgenic rat models for mutagenesis and carcinogenesisEvaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and D-mannitol.Diethylstilbestrol (DES): carcinogenic potential in Xpa-/-, Xpa-/- / p53+/-, and wild-type mice during 9 months' dietary exposure.DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?Evaluation of the carcinogenic potential of clofibrate in the neonatal mouse.The use of genetically modified mice in cancer risk assessment: challenges and limitations.Oncogenicity evaluation of resveratrol in p53(+/-) (p53 knockout) mice.Power, expertise and the limits of representative democracy: genetics as scientific progress or political legitimation in carcinogenic risk assessment of pharmaceuticals?Mouse models incorporating alterations in the major tumor suppressor genes P53 and P16: their use in screening for potential carcinogens, developing further relevant mouse models, and screening for potential chemopreventive and chemotherapetutic ageA tiered approach to systemic toxicity testing for agricultural chemical safety assessment.Nasal cytotoxic and carcinogenic activities of systemically distributed organic chemicals.Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?Benzene-induced hematopoietic neoplasms including myeloid leukemia in Trp53-deficient C57BL/6 and C3H/He mice.An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia.A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk.The genetic toxicity of methylphenidate: a review of the current literature.A critical appraisal of the process of regulatory implementation of novel in vivo and in vitro methods for chemical hazard and risk assessment.Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention.Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studies.Investigations of clofibrate in alternative carcinogenicity models.Evaluation of the carcinogenic potential of clofibrate in the p53+/- mouse.Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after oral administration--part I.Evaluation of the carcinogenic potential of clofibrate in the FVB/Tg.AC mouse after dermal application--part II.Studies evaluating the utility of N-methyl-N-nitrosourea as a positive control in carcinogenicity studies in the p53+/- mouse.Immunohistochemical Characterization of Sarcomas in Trp53+/- Haploinsufficient Mice.Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role for metabolic and oxidative stress in nongenotoxic carcinogenicity.An integrative test strategy for cancer hazard identification.
P2860
Q23901998-23699BB1-033D-4207-9F30-33B1A30358BAQ24298517-49FD04B9-0A88-4FFF-8E0C-484D996E834AQ24806937-2063CE0A-A66A-473E-B212-6094A34A6C87Q24814156-3AD3B188-82B2-498D-BB53-219DF52B0CCCQ28817612-A74168CD-5908-4ECE-8B93-44D7C9C60AB1Q33203784-83EF3797-AF3C-49A6-8376-43585212B61EQ33223773-7BD89E23-8C21-461D-B49F-D57284EF9931Q33399015-F63D19CC-E3B2-4FF1-8311-622725132573Q34463834-0CAEC807-E20D-4B1B-B20C-D8944D592AFEQ35688431-B93914AD-F1AA-4040-978A-BD385C23D328Q35758133-8C98C948-F32A-4253-9B0F-0CE60C31FA2AQ35854569-EC35EBF7-4C39-4551-9EAB-4828D8AF70ECQ36070444-25FCC95D-5FBC-4734-B5C9-F5D1DD52AEDDQ36481766-6534EDC9-2025-42B4-A022-769731FE6E49Q36688003-068F5F3B-C1E2-419E-BBCE-C03F69B6E751Q37187425-737C6B8B-EEDC-49DF-AC45-9E308BABC932Q37256614-1C445804-2202-47EF-AFFF-9CE29408194CQ37628343-5AECA4D1-9295-4443-91E9-6964F52D7078Q37633279-1653ED29-8F6D-4F01-B377-2CCCA6F61D12Q37795414-7BD9F441-2058-464C-872A-229E2F38C7EDQ37850626-BD12A165-7116-459C-A1B0-92CB8C63CFC4Q37984211-4B2565EB-378F-4026-A4BF-E863E2BF47B9Q38233531-1462C9DF-00BE-400C-B45E-408FD1347DEBQ43119645-6D546D68-A543-44EC-BF99-8595B228B31EQ44269651-C7449F5B-2D8B-4A8A-8F5A-BF18E86BA7A6Q46269041-48C10208-3FAA-4B64-ABB5-B8F6A859A85FQ46338587-4BE6E6EA-59B3-415B-8550-2AF609A56473Q46781510-3E58454C-8FD9-429C-8BEF-1CBD668841A9Q46781515-E14EF061-7288-4FA9-A44F-DA0F8C19FD5BQ46781520-C621DEAF-3506-487D-B730-63840BE10D5BQ46781523-4A02BA1C-C2F3-458A-8925-0DABE583CB32Q46781526-CE7E8A78-2807-4027-B68F-36406A28A4DFQ46781535-22C8632F-47AC-44D3-826A-D05AECB82A57Q48165665-B4F7837C-3C4F-4965-9C8C-F0794A69A33AQ48605988-731FEE38-A258-4CEC-85F9-5E8F90636609Q50856445-8863245D-6603-4DA3-BB87-320F7D8E24E8
P2860
P53+/- hemizygous knockout mouse: overview of available data.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
P53+/- hemizygous knockout mouse: overview of available data.
@ast
P53+/- hemizygous knockout mouse: overview of available data.
@en
type
label
P53+/- hemizygous knockout mouse: overview of available data.
@ast
P53+/- hemizygous knockout mouse: overview of available data.
@en
prefLabel
P53+/- hemizygous knockout mouse: overview of available data.
@ast
P53+/- hemizygous knockout mouse: overview of available data.
@en
P2093
P1476
P53+/- hemizygous knockout mouse: overview of available data.
@en
P2093
E K LeGrand
J E French
J E Sagartz
L A Mixson
R D Storer
P356
10.1080/019262301753178465
P407
P478
P577
2001-01-01T00:00:00Z